Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000285596 | SCV000342884 | uncertain significance | not provided | 2018-06-07 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV001163869 | SCV001325953 | uncertain significance | Peroxisome biogenesis disorder 5A (Zellweger) | 2018-03-30 | criteria provided, single submitter | clinical testing | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. |
Invitae | RCV001163869 | SCV001417513 | uncertain significance | Peroxisome biogenesis disorder 5A (Zellweger) | 2022-11-01 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 108 of the PEX2 protein (p.Val108Leu). This variant is present in population databases (rs148101729, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with PEX2-related conditions. ClinVar contains an entry for this variant (Variation ID: 288695). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt PEX2 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV003165763 | SCV003870844 | uncertain significance | Inborn genetic diseases | 2023-01-24 | criteria provided, single submitter | clinical testing | The c.322G>C (p.V108L) alteration is located in exon 4 (coding exon 1) of the PEX2 gene. This alteration results from a G to C substitution at nucleotide position 322, causing the valine (V) at amino acid position 108 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001828256 | SCV002083371 | uncertain significance | Zellweger spectrum disorders | 2019-10-28 | no assertion criteria provided | clinical testing |